Media about us

28 August 2015

Syndax adds Genentech PD-L1 'atezo' combo pact to its growing pipeline

John Carroll / FierceBiotech

Genentech has agreed to lend its closely-watched checkpoint inhibitor atezolizumab to Syndax for a combo study with the Waltham, MA-based biotech's lead drug entinostat for triple-negative breast cancer, just three days after Syndax landed an $80 million crossover round.

25 August 2015

Syndax banks an $80M crossover round for PhIII cancer drug

John Carroll / FierceBiotech

Two months after signing up AstraZeneca ($AZN) R&D leader Briggs Morrison as its new CEO, Waltham, MA-based Syndax has raised $80 million from a syndicate that includes a group of high-profile crossover investors.

24 August 2015

New CEO and $80M Later, Syndax Looks Prepped for Second IPO Try

Ben Filder / Xconomy

If Syndax Pharmaceuticals’ latest financing is any indication, the Waltham, MA-based firm looks to have another shot at an initial public offering in mind.

Epic's CSO Dena Marinucci Named to Pharmavoice 100

PharmaVoice.com

PharmaVOICE has named Dena Marinucci, Ph.D. CSO of Epic Sciences, to the magazine's 2015 list of 100 outstanding professionals in the life-sciences industry.  Dena was chosen as part of the group of visionary entrepreneurs who recognized an opportunity to fill an industry need and are successfully leading their companies to new heights.

09 July 2015

Epic Sciences and LabCorp expand global reach with Asia clinical trials deal

Emily Wasserman / FierceDiagnostics

Last year, San Diego's Epic Sciences said it would team up with diagnostics luminary LabCorp ($LH) to make its tests available for European clinical trials. Now the companies are expanding their global footprint, extending their collaboration to provide Epic's tools for cancer clinical trials in Asia.

02 July 2015

Corneal inlay for presbyopia shows promise without added visual problems in pseudophakes

Lynda Charters; Ralph Chu, MD / Ophthalmology Times

Initial results with an investigational device for correcting presbyopia (Raindrop Near Vision Inlay, Revision Optics) are promising. The device improves near visual performance without added visual disturbance in pseudophakic patients.

29 June 2015

NovaMedica to develop up to 15 nano-drugs by 2020

Interfax. Russia & CIS Health & Pharmaceuticals

LLC NovaMedica (Moscow) is planning to intensify research work to develop a portfolio of its own pharmaceutical products with the use of nano-technology. It is going to develop up to 15 innovative drugs within the coming seven years, most of which will be based on nano-technologies, the company said in a report.

17 June 2015

Celtaxsys $40.00 million Fundraising. William P Reddick Submitted Jun 10 SEC Form

Octafinance.com

Celtaxsys, Inc., Corporation just released form D for $40.00 million equity financing. This is a new filing. Celtaxsys was able to sell $21.63 million so far. That is 54.07% of the financing round. The total offering amount was $40.00 million. The fundraising form was filled on 2015-06-10. The reason for the financing was: unspecified. The fundraising still has about $18.37 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.

16 June 2015

Tobira Finishes Patient Enrollment for NASH Study

Leonor Mateus Ferreira / Hepatitis News Today

Tobira Therapeutics, Inc. has finished recruiting patients for its phase 2b CENTAURstudy, which was designed to evaluate a therapy called cenicriviroc (CVC) in patients who suffer from non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company, which is focused on developing and commercializing therapeutic options to treat liver and inflammatory conditions, announced enrollment completion in a press release.

16 June 2015

Coda Therapeutics $3.43 million Fundraising. David Pool Published Jun 12 SEC Filing

Octafinance.com

Coda Therapeutics Inc, Corporation just submitted form D announcing $3.43 million debt financing. This is a new filing. Coda Therapeutics was able to finance itself with $1.21 million so far. That is 35.16% of the financing offer. The total private financing amount was $3.43 million. The form was filled on 2015-06-12. The reason for the financing was: Total Offering Amount includes estimated amounts receivable by the Issuer upon the exercise of certain warrants to purchase the Issuer’s preferred stock (assuming no net issue exercise, where applicable).